Clinicopathological characteristics of the patients in the training and validation cohorts
| Variables . | Training cohort (n = 238) . | Validation cohort (n = 183) . | P . |
|---|---|---|---|
| Age (years) (median, i.q.r.) | 58.50 (51–64) | 56.00 (48–66) | 0.165 |
| Sex | |||
| Male | 139 (58.4) | 122 (66.7) | 0.083 |
| Female | 99 (41.6) | 61 (33.3) | |
| Preoperative CEA level | 0.593 | ||
| Normal | 153 (64.3) | 113 (61.7) | |
| Elevated | 85 (35.7) | 70 (38.3) | |
| SII | 0.935 | ||
| Low | 118 (49.6) | 90 (49.2) | |
| High | 120 (50.4) | 93 (50.8) | |
| Distance from the anal verge (cm) | 0.267 | ||
| <5 | 117 (49.2) | 80 (43.7) | |
| ≥5 | 121 (50.8) | 103 (56.3) | |
| Surgical approach | 0.361 | ||
| Low anterior resection | 170 (71.4) | 138 (75.4) | |
| Other procedures* | 68 (28.6) | 45 (24.6) | |
| Tumour differentiation | 0.190 | ||
| Well | 40 (16.8) | 40 (21.9) | |
| Moderate + poor | 198 (83.2) | 143 (78.1) | |
| ypT stage | 0.873 | ||
| ypT1–2 | 141 (59.2) | 107 (58.5) | |
| ypT3–4 | 97 (40.8) | 76 (41.5) | |
| ypN stage | 0.670 | ||
| ypN0 | 171 (71.8) | 128 (69.9) | |
| ypN+ | 67 (28.2) | 55 (30.1) | |
| TRG | 0.203 | ||
| TRG 1 | 91 (38.2) | 59 (32.2) | |
| TRG 2–3 | 147 (61.8) | 124 (67.8) | |
| Adjuvant treatment | 0.248 | ||
| Yes | 213 (89.5) | 157 (85.8) | |
| No | 25 (10.5) | 26 (14.2) | |
| Collagen signature (median, i.q.r.) | −0.166 (−0.388–0.119) | −0.166 (−0.336–0.196) | 0.468 |
| Variables . | Training cohort (n = 238) . | Validation cohort (n = 183) . | P . |
|---|---|---|---|
| Age (years) (median, i.q.r.) | 58.50 (51–64) | 56.00 (48–66) | 0.165 |
| Sex | |||
| Male | 139 (58.4) | 122 (66.7) | 0.083 |
| Female | 99 (41.6) | 61 (33.3) | |
| Preoperative CEA level | 0.593 | ||
| Normal | 153 (64.3) | 113 (61.7) | |
| Elevated | 85 (35.7) | 70 (38.3) | |
| SII | 0.935 | ||
| Low | 118 (49.6) | 90 (49.2) | |
| High | 120 (50.4) | 93 (50.8) | |
| Distance from the anal verge (cm) | 0.267 | ||
| <5 | 117 (49.2) | 80 (43.7) | |
| ≥5 | 121 (50.8) | 103 (56.3) | |
| Surgical approach | 0.361 | ||
| Low anterior resection | 170 (71.4) | 138 (75.4) | |
| Other procedures* | 68 (28.6) | 45 (24.6) | |
| Tumour differentiation | 0.190 | ||
| Well | 40 (16.8) | 40 (21.9) | |
| Moderate + poor | 198 (83.2) | 143 (78.1) | |
| ypT stage | 0.873 | ||
| ypT1–2 | 141 (59.2) | 107 (58.5) | |
| ypT3–4 | 97 (40.8) | 76 (41.5) | |
| ypN stage | 0.670 | ||
| ypN0 | 171 (71.8) | 128 (69.9) | |
| ypN+ | 67 (28.2) | 55 (30.1) | |
| TRG | 0.203 | ||
| TRG 1 | 91 (38.2) | 59 (32.2) | |
| TRG 2–3 | 147 (61.8) | 124 (67.8) | |
| Adjuvant treatment | 0.248 | ||
| Yes | 213 (89.5) | 157 (85.8) | |
| No | 25 (10.5) | 26 (14.2) | |
| Collagen signature (median, i.q.r.) | −0.166 (−0.388–0.119) | −0.166 (−0.336–0.196) | 0.468 |
Values in parentheses are percentages unless indicated otherwise. *Other procedures included: abdominoperineal resection, intersphincteric resection and transanal total mesorectal excision. i.q.r.,interquartile range; CEA, carcinoembryonic antigen; SII, systemic immune-inflammation index; TRG, tumour regression grade; ypN, lymph node status after neoadjuvant treatment; ypT, tumour stage after neoadjuvant treatment.
Clinicopathological characteristics of the patients in the training and validation cohorts
| Variables . | Training cohort (n = 238) . | Validation cohort (n = 183) . | P . |
|---|---|---|---|
| Age (years) (median, i.q.r.) | 58.50 (51–64) | 56.00 (48–66) | 0.165 |
| Sex | |||
| Male | 139 (58.4) | 122 (66.7) | 0.083 |
| Female | 99 (41.6) | 61 (33.3) | |
| Preoperative CEA level | 0.593 | ||
| Normal | 153 (64.3) | 113 (61.7) | |
| Elevated | 85 (35.7) | 70 (38.3) | |
| SII | 0.935 | ||
| Low | 118 (49.6) | 90 (49.2) | |
| High | 120 (50.4) | 93 (50.8) | |
| Distance from the anal verge (cm) | 0.267 | ||
| <5 | 117 (49.2) | 80 (43.7) | |
| ≥5 | 121 (50.8) | 103 (56.3) | |
| Surgical approach | 0.361 | ||
| Low anterior resection | 170 (71.4) | 138 (75.4) | |
| Other procedures* | 68 (28.6) | 45 (24.6) | |
| Tumour differentiation | 0.190 | ||
| Well | 40 (16.8) | 40 (21.9) | |
| Moderate + poor | 198 (83.2) | 143 (78.1) | |
| ypT stage | 0.873 | ||
| ypT1–2 | 141 (59.2) | 107 (58.5) | |
| ypT3–4 | 97 (40.8) | 76 (41.5) | |
| ypN stage | 0.670 | ||
| ypN0 | 171 (71.8) | 128 (69.9) | |
| ypN+ | 67 (28.2) | 55 (30.1) | |
| TRG | 0.203 | ||
| TRG 1 | 91 (38.2) | 59 (32.2) | |
| TRG 2–3 | 147 (61.8) | 124 (67.8) | |
| Adjuvant treatment | 0.248 | ||
| Yes | 213 (89.5) | 157 (85.8) | |
| No | 25 (10.5) | 26 (14.2) | |
| Collagen signature (median, i.q.r.) | −0.166 (−0.388–0.119) | −0.166 (−0.336–0.196) | 0.468 |
| Variables . | Training cohort (n = 238) . | Validation cohort (n = 183) . | P . |
|---|---|---|---|
| Age (years) (median, i.q.r.) | 58.50 (51–64) | 56.00 (48–66) | 0.165 |
| Sex | |||
| Male | 139 (58.4) | 122 (66.7) | 0.083 |
| Female | 99 (41.6) | 61 (33.3) | |
| Preoperative CEA level | 0.593 | ||
| Normal | 153 (64.3) | 113 (61.7) | |
| Elevated | 85 (35.7) | 70 (38.3) | |
| SII | 0.935 | ||
| Low | 118 (49.6) | 90 (49.2) | |
| High | 120 (50.4) | 93 (50.8) | |
| Distance from the anal verge (cm) | 0.267 | ||
| <5 | 117 (49.2) | 80 (43.7) | |
| ≥5 | 121 (50.8) | 103 (56.3) | |
| Surgical approach | 0.361 | ||
| Low anterior resection | 170 (71.4) | 138 (75.4) | |
| Other procedures* | 68 (28.6) | 45 (24.6) | |
| Tumour differentiation | 0.190 | ||
| Well | 40 (16.8) | 40 (21.9) | |
| Moderate + poor | 198 (83.2) | 143 (78.1) | |
| ypT stage | 0.873 | ||
| ypT1–2 | 141 (59.2) | 107 (58.5) | |
| ypT3–4 | 97 (40.8) | 76 (41.5) | |
| ypN stage | 0.670 | ||
| ypN0 | 171 (71.8) | 128 (69.9) | |
| ypN+ | 67 (28.2) | 55 (30.1) | |
| TRG | 0.203 | ||
| TRG 1 | 91 (38.2) | 59 (32.2) | |
| TRG 2–3 | 147 (61.8) | 124 (67.8) | |
| Adjuvant treatment | 0.248 | ||
| Yes | 213 (89.5) | 157 (85.8) | |
| No | 25 (10.5) | 26 (14.2) | |
| Collagen signature (median, i.q.r.) | −0.166 (−0.388–0.119) | −0.166 (−0.336–0.196) | 0.468 |
Values in parentheses are percentages unless indicated otherwise. *Other procedures included: abdominoperineal resection, intersphincteric resection and transanal total mesorectal excision. i.q.r.,interquartile range; CEA, carcinoembryonic antigen; SII, systemic immune-inflammation index; TRG, tumour regression grade; ypN, lymph node status after neoadjuvant treatment; ypT, tumour stage after neoadjuvant treatment.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
